How 23andMe’s gene-testing dream turned recessive
She has resigned from the former; the latter does not matter since 23andMe’s equity could be wiped out. If persistence pays off, a company that started out as little more than an intriguing idea and a ...
PharmiWeb21h
New study results reinforce Tagrisso as the backbone therapy for EGFR-mutated lung cancer across stages and settings
New study results presented at the European Lung Cancer Congress (ELCC) 2025, 26 to 29 March, demonstrate the role of AstraZeneca’s Tagrisso (osimertinib), as monotherapy and as the backbone for novel ...
Le Lézard8h
New study results reinforce TAGRISSO® (osimertinib) as the backbone therapy for EGFR-mutated lung cancer across stages and settings
New study results presented at the European Lung Cancer Congress (ELCC) 2025, March 26 to 29, demonstrate the role of AstraZeneca's TAGRISSO® (osimertinib), as monotherapy and as the backbone for ...